Application of daceobavir ABT-333 in preparation of medicine for preventing and treating rotavirus
By discovering that dasephuvir ABT-333 can inhibit rotavirus replication and VP6 protein expression, it solves the problem of no effective drug for treating rotavirus, provides an effective drug regimen, significantly reduces viral replication and cell replication Low toxicity.
Patent Information
- Application Number
- CN202411347769.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-26
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There are no effective commercial drugs available for the treatment of rotavirus, especially in countries with poor sanitation and high mortality rates, and the antiviral effect of dasephuvir ABT-333 on rotavirus is not clear .
Through research, dascebvir ABT-333 can significantly inhibit rotavirus replication and transcription and expression of VP6 protein, and is less cytotoxic, so it can be used to prepare drugs to prevent and treat rotavirus.
Dasebvi ABT-333 significantly inhibits rotavirus replication, reduces VP6 protein expression, and is less cytotoxic, providing an effective drug choice for the treatment of rotavirus.
Smart Images

Figure CN119033786A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, in particular to application of dasabuvir ABT-333 in preparing medicines for preventing and treating rotavirus. Background Art
[0002] Rotavirus (RV) enteritis is an acute gastrointestinal infectious disease caused by rotavirus. The pathogen is mainly transmitted through the digestive tract. Infants and young children are susceptible to it. It is often caused by group A rotavirus. There is currently no commercial drug for the treatment of rotavirus, so the development of effective anti-rotavirus drugs is of great significance for the treatment of rotavirus. In some countries with poor sanitary conditions, the morbidity and mortality of rotavirus are very high due to the lack of popularization of vaccines.
[0003] RV is a non-enveloped double-stranded RNA virus, the core of which is a genome of 11 dsRNA segments, surrounded by three capsid proteins. The RNA segments encode six structural proteins (VP1, VP2, VP3, VP4, VP6, VP7) and six non-structural proteins (NSP1, NSP2, NSP3, NSP4, NSP5, NSP6). Among them, VP6 protein accounts for 15% of the total protein, has strong immunogenicity, is located in the middle layer of the virus and is highly conserved. It is the inner capsid protein that maintains the stability of the virus particles; in addition, VP6 protein plays an important role in the replication and assembly of rotavirus. It not only participates in the participation of gene transcriptase and replicase, but also activates transcriptase and promotes the synthesis of mRNA.
[0004] Dasabuvir (ABT-333) has a molecular formula of C26H27N3O5S and a CAS number of 1132935-63-7. Dasabuvir is a non-nucleoside inhibitor of the RNA-dependent RNA polymerase encoded by the NS5B gene of hepatitis C virus (HCV) and is approved for the treatment of hepatitis C virus infection. Dasabuvir has good safety and tolerability and is often used in combination with other drugs. In the treatment of hepatitis C, the multi-target therapy of combining ABT-450, ABT-267, ABT-333 and ribavirin is very effective. In addition, Dasabuvir, Efavirenz, Tipranavir, or both can inhibit the replication of multiple flaviviruses in Vero cells in vitro. However, it is not clear whether Dasabuvir ABT-333 has an antiviral effect on rotavirus.
[0005] Therefore, there is an urgent need to study drugs based on dasabuvir ABT-333 for the prevention and treatment of rotavirus. Summary of the invention
[0006] In order to solve the above technical problems, the present invention provides the use of dasabuvir ABT-333 in the preparation of drugs for preventing and treating rotavirus.
[0007] To achieve the above object, the present invention is implemented according to the following technical solutions:
[0008] One of the purposes of the present invention is to provide the use of dasabuvir ABT-333 as the sole active ingredient in the preparation of a drug for preventing and treating rotavirus.
[0009] The second object of the present invention is to provide a drug for preventing and treating rotavirus, comprising dasabuvir ABT-333.
[0010] Furthermore, the drug for preventing and treating rotavirus also contains a pharmaceutically acceptable carrier and / or excipient.
[0011] Furthermore, the dosage form of the drug is one of tablets, sprays, granules, capsules, oral liquids, injections, and suspensions.
[0012] Compared with the prior art, the present invention found that dasabuvir ABT-333 can significantly inhibit rotavirus replication, and found that dasabuvir ABT-333 can significantly inhibit the transcription and protein expression level of VP6, and dasabuvir ABT-333 has little cytotoxicity. Therefore, the small molecule compound dasabuvir ABT-333 can be used to treat rotavirus. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 The fluorescence graph of the compound Dasabuvir ABT-333 inhibiting rotavirus: the FITC and TRANS rows were observed under green fluorescence and white light, respectively; the 2.5μM, 5μM, and 10μM columns indicated that Caco-2 cells were treated with RV virus solution + DMSO (0μM), RV virus solution, and different concentrations of Dasabuvir (2.5μM, 5μM, and 10μM), respectively; the zoverlay row superimposed the green fluorescence and white light.
[0014] Figure 2 The figures are comparisons of the inhibitory effects of different concentrations of the compound dasabuvir ABT-333 on RV virus: A is a comparison of the inhibitory effects on RV virus replication; B is a fitting curve of the inhibition rate on the RV virus genome copy number.
[0015] Figure 3 The compound dasabuvir ABT-333 inhibits the expression of rotavirus VP6 protein.
[0016] Figure 4 The figure shows the results of cytotoxicity test. DETAILED DESCRIPTION
[0017] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The specific embodiments described herein are only used to explain the present invention and are not used to limit the invention.
[0018] The human cloned colon adenocarcinoma cells (Caco-2 cells) used in the following examples were preserved by the Guangdong Provincial Key Laboratory of Animal Molecular Design and Precision Breeding and cultured in a 37°C, 5% CO2 incubator. The compound dasabuvir ABT-333 used was purchased from Shanghai Yuanye Biotechnology Co., Ltd., and its chemical molecular structure is shown below:
[0019]
[0020] The different concentrations of Dasabuvir used in the following examples were prepared by first diluting Dasabuvir with DMSO to a concentration of 10 mM, and then diluting it with DMEM medium to 1.25 μM, 2.5 μM, 5 μM, 10 μM, and 20 μM.
[0021] Other related reagents used, unless otherwise specified, are all commercially available agents, and the methods involved, unless otherwise specified, are all well-known methods.
[0022] Rotavirus strains used: Rotavirus vaccine strain LLR (G10P
[15] ), maintained by the Viral Diarrhea Laboratory of the Chinese Center for Disease Control and Prevention, subcultured on MA104 cells; MA104 cells (African green monkey embryonic kidney cells), maintained by the Viral Diarrhea Laboratory of the Chinese Center for Disease Control and Prevention, passage number 23.
[0023] In order to verify whether Dasabuvir ABT-333 (Dasabuvir) can be used as the only active ingredient to prepare drugs for the prevention and treatment of rotavirus (RV), the following tests were conducted:
[0024] 1. Observation of the effect of compound dasabuvir ABT-333 on RV infection and replication under fluorescence
[0025] Caco-2 (2×10 6 / well), the experimental group was inoculated with rotavirus (MOI = 0.01), and then treated with Dasabuvir at concentrations of 2.5μM, 5μM, and 10μM, respectively. The blank control group was treated with cells without rotavirus and culture medium. The infected control group treated cells with rotavirus and DMSO. Then the cell plate was placed at 37°C and 5% CO2 for 24 hours, and then the supernatant was discarded, rinsed three times with PBS, and fixed with 4% formaldehyde for 30 minutes. Then it was permeabilized by treating with 0.3% Triton for 10 minutes. After that, it was blocked with 5% BSA at room temperature for 1 hour, the blocking solution was discarded, and the antibody diluted with 5% BSA (rotavirus VP6 monoclonal antibody, dilution of 1:200) was added, and incubated at 4°C in the dark overnight. Then, the fluorescent secondary antibody labeled with fluorescein isothiocyanate (FITC) was incubated at 37°C for 1 hour. After incubation, the antibody was discarded, the membrane was washed three times with PBST, and the fluorescence changes were observed under a fluorescence microscope.
[0026] The experimental results are as follows Figure 1 As shown, Figure 1 It shows that under fluorescence and white light, the fluorescence in the infection control group (DMSO+RV) is brighter, and the fluorescence gradually dims after treatment with different concentrations of Dasabuvir. When treated with 10μM Dasabuvir, the fluorescence almost disappears. The above results show that the compound Dasabuvir can significantly inhibit the infection and replication of RV, and the inhibition becomes more obvious as the concentration of the compound increases.
[0027] 2. Effect of the compound dasabuvir ABT-333 on viral gene copy number during RV infection and replication
[0028] Caco-2 cells (2×10 6 / well), the experimental group treated cells with RV (MOI = 0.01) mixed with different concentrations of Dasabuvir (1.25μM, 2.5μM, 5μM, 10μM, 20μM) dissolved in DMSO. In addition, cells treated with rotavirus and DMSO were used as infection blank groups. The cell plate was then placed at 37°C and 5% CO2 for 24 hours, and then the cell samples were taken to extract RNA and reverse transcribed into cDNA, and the number of viral genome copies was detected by fluorescent quantitative PCR targeting the RVNSP3 gene. The total volume of the RT-qPCR reaction system was 25μL, including 12.5μL of Premix Ex Taq (Probe qPCR), 1μL of upstream and downstream primers, 0.5μL of RV probe primer, 2μL of template, and sterile deionized water was added to 25μL. The reaction conditions were: 95℃, 30s; 95℃, 5s, 60℃, 30s, for a total of 40 cycles.
[0029] Among them, the upstream primer of RV-NSP3 is: ACCATCTWCACRTRACCCTCTATGAG; the downstream primer is: GGTCACATAACGCCCCTATAGC; the RV probe primer is: FAM-AGTTAAAAG CTAACACTGTCAAA-MGB.
[0030] The results of the RV viral genome copy number experiment are as follows Figure 2 As shown, Figure 2 A in the figure is a comparison chart of the inhibitory effects of different concentrations of Dasabuvir on RV replication. The figure shows that the addition of Dasabuvir has a significant inhibitory effect on the RV viral genome copy number, and the inhibition rate can be as high as more than 80% at concentrations of 5μM, 10μM, and 20μM; Figure 2 B is the fitting curve of the inhibition rate of RV viral genome copy number after adding different concentrations of Dasabuvir. The figure shows that the IC of compound Dasabuvir ABT-333 inhibits RV 50 The value is 1.802μM.
[0031] 3. Effect of the compound dasabuvir ABT-333 on the expression level of RV VP6 protein
[0032] Caco-2 cells (2×10 6 / well), the experimental group was treated with rotavirus (MOI = 0.01) mixed with different concentrations of Dasabuvir (2.5μM, 5μM, 10μM) dissolved in DMSO, and the infection control group was treated with RV (MOI = 0.01) mixed with DMSO. The cells were then placed at 37°C, 5% CO2 and cultured for 24 hours, and the cell culture was collected, centrifuged, and the supernatant was discarded. After adding 1×SDS-PAGE loading buffer, the protein was denatured (100℃, 10min), centrifuged for 10min (12000r / min), the supernatant was collected, the supernatant was subjected to electrophoresis (120V, 30min), and the membrane was transferred to a 0.2μm nitrocellulose membrane (NC membrane) (100V, 1h), and then blocked with 5% skimmed milk powder for 1h, the blocking solution was discarded, 1×TBST was added to wash the membrane, and then the primary antibody was added and incubated in a 4℃ refrigerator overnight, the NC membrane was washed with 1×TBST, the secondary antibody was added and incubated for 1h, and the membrane was washed with 1×TBST and exposed using ECL luminescent liquid to detect the expression difference of VP6 protein.
[0033] The experimental results are as follows Figure 3As shown, compared with the uninfected control group, the VP6 protein expression level in the infected control group (DMSO) and the experimental group (Dasabuvir+RV) increased; however, compared with the infected control group (DMSO), the VP6 protein expression level in the experimental group (Dasabuvir+RV) was significantly reduced. The results show that the compound Dasabuvir can significantly inhibit the expression level of VP6 protein in the rotavirus gene.
[0034] 4. Cytotoxicity of the compound Dasabuvir ABT-333
[0035] The cytotoxicity of the small molecule dasabuvir ABT-333 was tested on Caco-2 cells using the CCK-8 method. Caco-2 cells (2×10 5 / well), DMSO was added to the wells to dissolve different concentrations of Dasabuvir (1.25μM, 2.5μM, 5μM, 10μM, 20μM) to treat the cells as the experimental group, and a blank control group (culture medium + DMSO) and a negative control group (cells + culture medium + DMSO) were set up at the same time. The culture plate was incubated in an incubator for 24h, 10μL of CCK-8 solution was added to each well of the plate, and the culture plate was incubated in the incubator for another 4 hours. The absorbance at 450nm was measured using an enzyme reader, and the formula [(OD 实验组 -OD 空白对照组 ) / (OD 阴性对照 -OD 空白对照组 )×100%] to calculate the cell survival rate at each concentration.
[0036] The results are as follows Figure 4 As shown, the compound dasabuvir ABT-333 has low toxicity to cells, and even when it reaches 20 μM, the cell survival rate can still reach more than 90%, indicating low cytotoxicity. In summary, the compound dasabuvir ABT-333 of the present invention has a good inhibitory effect on sheep rotavirus and has low cytotoxicity, and can be used to treat rotavirus.
[0037] In summary, dasabuvir ABT-333 can be used as the sole active ingredient to prepare drugs for the prevention and treatment of rotavirus. Of course, the prepared drugs contain dasabuvir ABT-333 and also contain pharmaceutically acceptable carriers and / or excipients; the dosage form of the drug is one of tablets, sprays, granules, capsules, oral solutions, injections, and suspensions.
[0038] The technical solution of the present invention is not limited to the above-mentioned specific embodiments. All technical variations made according to the technical solution of the present invention fall within the protection scope of the present invention.
Claims
1. The use of dasabuvir ABT-333 as the sole active ingredient in the preparation of drugs for the prevention and treatment of rotavirus.
2. A drug for preventing and treating rotavirus, characterized in that: Contains dasabuvir ABT-333.
3. The drug for preventing and treating rotavirus according to claim 2, characterized in that: It also contains pharmaceutically acceptable carriers and / or excipients.
4. The drug for preventing and treating rotavirus according to claim 2 or 3, characterized in that: The dosage form of the medicine is one of tablets, sprays, granules, capsules, oral liquids, injections and suspensions.
Citation Information
Patent Citations
Preparation method of bulk drug dasabuvir
CN107266373A
